Edgewise Therapeutics Inc
EWTX14.017USD
-0.133-0.94%
Market hours （ET）Quotes delayed by 15 min
1.48BMarket Cap
LossP/E TTM
More Details of Edgewise Therapeutics Inc Company
Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
Company Info
Ticker SymbolEWTX
Company nameEdgewise Therapeutics Inc
IPO dateMar 26, 2021
CEODr. Kevin Koch, Ph.D.
Number of employees110
Security typeOrdinary Share
Fiscal year-endMar 26
Address1715 38Th St
CityBOULDER
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code80301
Phone17202627002
Websitehttps://edgewisetx.com/
Ticker SymbolEWTX
IPO dateMar 26, 2021
CEODr. Kevin Koch, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Kevin Koch, Ph.D.
Dr. Kevin Koch, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
369.40K
+2.78%
Dr. Joanne M. Donovan, M.D., Ph.D.
Dr. Joanne M. Donovan, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.41K
+13.58%
Dr. Behrad Derakhshan, Ph.D.
Dr. Behrad Derakhshan, Ph.D.
Chief Operating Officer
Chief Operating Officer
23.64K
+16.16%
Dr. Badreddin Edris, Ph.D.
Dr. Badreddin Edris, Ph.D.
Independent Director, Co-Founder
Independent Director, Co-Founder
19.82K
--
Dr. Jonathan D. (Jon) Root, M.D.
Dr. Jonathan D. (Jon) Root, M.D.
Independent Director
Independent Director
15.63K
--
Dr. Jonathan C. Fox, M.D., Ph.D.
Dr. Jonathan C. Fox, M.D., Ph.D.
Independent Director
Independent Director
12.27K
+7.52%
Mr. John R. Moore
Mr. John R. Moore
General Counsel
General Counsel
5.03K
+273.83%
Dr. Alan Russell, Ph.D.
Dr. Alan Russell, Ph.D.
Chief Scientific Officer, Director, Co-Founder
Chief Scientific Officer, Director, Co-Founder
--
--
Mr. R. Michael Carruthers
Mr. R. Michael Carruthers
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Kevin Koch, Ph.D.
Dr. Kevin Koch, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
369.40K
+2.78%
Dr. Joanne M. Donovan, M.D., Ph.D.
Dr. Joanne M. Donovan, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.41K
+13.58%
Dr. Behrad Derakhshan, Ph.D.
Dr. Behrad Derakhshan, Ph.D.
Chief Operating Officer
Chief Operating Officer
23.64K
+16.16%
Dr. Badreddin Edris, Ph.D.
Dr. Badreddin Edris, Ph.D.
Independent Director, Co-Founder
Independent Director, Co-Founder
19.82K
--
Dr. Jonathan D. (Jon) Root, M.D.
Dr. Jonathan D. (Jon) Root, M.D.
Independent Director
Independent Director
15.63K
--
Dr. Jonathan C. Fox, M.D., Ph.D.
Dr. Jonathan C. Fox, M.D., Ph.D.
Independent Director
Independent Director
12.27K
+7.52%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
14.73%
RA Capital Management, LP
9.40%
Baker Bros. Advisors LP
6.94%
Paradigm BioCapital Advisors LP
5.83%
Janus Henderson Investors
5.22%
Other
57.88%
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
14.73%
RA Capital Management, LP
9.40%
Baker Bros. Advisors LP
6.94%
Paradigm BioCapital Advisors LP
5.83%
Janus Henderson Investors
5.22%
Other
57.88%
Shareholder Types
Shareholders
Proportion
Hedge Fund
26.25%
Investment Advisor
21.79%
Private Equity
21.25%
Investment Advisor/Hedge Fund
19.40%
Venture Capital
14.90%
Research Firm
1.97%
Individual Investor
0.51%
Pension Fund
0.24%
Bank and Trust
0.17%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
392
106.86M
101.57%
-4.27M
2025Q1
393
107.86M
104.23%
-2.02M
2024Q4
367
101.45M
106.62%
-4.12M
2024Q3
338
103.17M
110.02%
-3.61M
2024Q2
297
103.29M
110.57%
-1.75M
2024Q1
271
99.64M
106.68%
+5.45M
2023Q4
244
81.22M
115.32%
+5.36M
2023Q3
218
69.97M
110.26%
-9.47M
2023Q2
215
71.14M
112.43%
-5.61M
2023Q1
210
68.18M
108.02%
-8.97M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
OrbiMed Advisors, LLC
15.25M
14.5%
-265.63K
-1.71%
May 12, 2025
RA Capital Management, LP
8.91M
8.47%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
6.16M
5.85%
--
--
Mar 31, 2025
Paradigm BioCapital Advisors LP
4.39M
4.18%
-344.37K
-7.27%
Mar 31, 2025
Janus Henderson Investors
5.28M
5.02%
+298.21K
+5.98%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.39M
5.13%
+31.84K
+0.59%
Mar 31, 2025
Novo Holdings A/S
5.35M
5.09%
+350.00K
+7.00%
Mar 31, 2025
Braidwell LP
2.46M
2.34%
+126.61K
+5.43%
Mar 31, 2025
The Vanguard Group, Inc.
4.29M
4.07%
-172.44K
-3.87%
Mar 31, 2025
Perceptive Advisors LLC
6.55M
6.22%
+1.38M
+26.78%
Mar 31, 2025
View more
Related ETFs
Updated: Wed, Aug 6
Updated: Wed, Aug 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
2.7%
SPDR S&P Pharmaceuticals ETF
2.05%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.27%
ALPS Medical Breakthroughs ETF
0.93%
Virtus LifeSci Biotech Clinical Trials ETF
0.77%
iShares U.S. Pharmaceuticals ETF
0.49%
Federated Hermes MDT Small Cap Core ETF
0.3%
iShares Health Innovation Active ETF
0.17%
First Trust Multi-Manager Small Cap Opportunities ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.15%
View more
iShares Neuroscience and Healthcare ETF
Proportion2.7%
SPDR S&P Pharmaceuticals ETF
Proportion2.05%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.27%
ALPS Medical Breakthroughs ETF
Proportion0.93%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.77%
iShares U.S. Pharmaceuticals ETF
Proportion0.49%
Federated Hermes MDT Small Cap Core ETF
Proportion0.3%
iShares Health Innovation Active ETF
Proportion0.17%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.15%
ProShares Ultra Nasdaq Biotechnology
Proportion0.15%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
